

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 12531-002001	Application No. 09/722,096
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Ernest G. Hope	
		Filing Date November 22, 2000	Group Art Unit 1623 / 64

RECEIVED

SEP 17 2001

TECH CENTER 1600/290

U.S. Patent Documents

Examiner Initial	Desig. ID	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date If Appropriate
CY	AA	5,660,827	08/26/97	Thorpe et al.			


Foreign Patent Documents or Published Foreign Patent Applications

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	AB							

Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
CY	AC	Antin, "Graft-Versus-Leukemia: No Longer an Epiphenomenon", <u>Blood</u> , 82:2273-2277 (1993)
CY	AD	Ayalon et al., "Induction of transporter associated with antigen processing by interferon γ confers endothelial cell cytoprotection against natural killer-mediated lysis", <u>Proc. Natl. Acad. Sci. USA</u> , 95:2435-2440 (1998)
CY	AE	Hauch et al., "Anti-Leukemia Potential of Interleukin-2 Activated Natural Killer Cells After Bone Marrow Transplantation for Chronic Myelogenous Leukemia", <u>Blood</u> , 75:2250-2262 (1990)
CY	AF	Hoyle et al., "Expansion of Philadelphia Chromosome-Negative CD3+CD56+ Cytotoxic Cells From Chronic Myeloid Leukemia Patients: In Vitro and In Vivo Efficacy in Severe Combined Immunodeficiency Disease Mice", <u>Blood</u> , 92:3318-3327 (1998)
CY	AG	Kolb et al., "Graft-Versus-Leukemia Effect of Donor Lymphocyte Transfusions in Marrow Grafted Patients", <u>Blood</u> , 86:2041-2050 (1995)
CY	AH	Kotasek et al., "Mechanism of Cultured Endothelial Injury Induced by Lymphokine-activated Killer Cells", <u>Cancer Research</u> , 48:5528-5532 (1988)
CY	AI	Lu et al., "A Novel Population of Expanded Human CD3+CD56+ Cells Derived from T Cells with Potent In Vivo Antitumor Activity in Mice with Severe Combined Immunodeficiency", <u>The Journal of Immunology</u> , 153:1687-1696 (1994)
CY	AJ	Martin et al., "Effects of In Vitro Depletion of T Cells in HLA-Identical Allogeneic Marrow Grafts", <u>Blood</u> , 66:664-672 (1985)
CY	AK	Mehta et al., "Two Pathways of Exocytosis of Cytoplasmic Granule Contents and Target Cell Killing by Cytokine-Induced CD3+CD56+ Killer Cells", <u>Blood</u> , 86:3493-3499 (1995)
CY	AL	Porter et al., "Induction of Graft-Versus-Host Disease as Immunotherapy for Relapsed Chronic Myeloid Leukemia", <u>The New England Journal of Medicine</u> , 330:100-106 (1994)
CY	AM	Rosenberg et al., "Regression of Established Pulmonary Metastases and Subcutaneous Tumor Mediated by the Systemic Administration of High-Dose Recombinant Interleukin 2", <u>J. Exp. Med.</u> 161:1169-1188 (1985)
CY	AN	Rosenberg et al., "Special Report, Use of Tumor-Infiltrating Lymphocytes and Interleukin-2 In the Immunotherapy of Patients with Metastatic Melanoma", <u>The New England Journal of Medicine</u> , 319:1676-1680 (1988)
CY	AO	Scheffold et al., "Potential of autologous immunologic effector cells for bone marrow purging in patients with chronic myeloid leukemia", <u>Stockton Press</u> , 33-39 (1994)

Examiner Signature <i>Christopher H. Y.</i>	Date Considered 12-4-02
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	



Sheet 2 of 2

TECH CENTER 1600/2900

SEP 17 2001

RECEIVED

Substitute Form PTO-1449 (Modified) Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 12531-002001	Application No. 09/722,096
	Applicant Ernest G. Hope		
	Filing Date November 22, 2000	Group Art Unit 1623	

Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
	AP	Schmidt-Wolf et al., "Phase I clinical study applying autologous immunological effector cells transfected with the interleukin-2 gene in patients with metastatic renal cancer, colorectal cancer and lymphoma", <u>British Journal of Cancer</u> , 81:1009-1016 (1999)
	AQ	Schmidt-Wolf et al. "Activated T cells and cytokine-induced CD3+ CD56+ killer cells", <u>Ann Hematol</u> , 74:51-56 (1997)
CY	AR	Schmidt-Wolf et al., "Sensitivity of Multidrug-Resistant Tumor Cell Lines to Immunologic Effector Cells", <u>Cellular Immunology</u> , 169:85-90 (1996)
CY	AS	Schmidt-Wolf et al., "Clinical Protocol, Interleukin-7 Gene Transfer in Patients with Metastatic Colon Carcinoma, Renal Cell Carcinoma, Melanoma, or with Lymphoma", <u>Human Gene Therapy</u> , 5:1161-1168 (1994)
CY	AT	Siegel et al., "Interleukin-2 Toxicity", <u>Journal of Clinical Oncology</u> , 9:694-704 (1991)
CY	AU	Stoner et al., "Heritable germ and somatic cell lineage competitions in chimeric colonial protochordates", <u>Proc. Natl. Acad. Sci. USA</u> , 96:9148-9153 (1999)
CY	AV	Sullivan et al. "Influence of Acute and Chronic Graft-Versus-Host Disease on Relapse and Survival After Bone Marrow Transplantation From HLA-Identical Siblings as Treatment of Acute and Chronic Leukemia", <u>Blood</u> , 73:1720-1728 (1989)
CY	AW	Weiden et al., "Antileukemic Effect of Graft-Versus-Host Disease in Human Recipients of Allogeneic-Marrow Grafts", <u>The New England Journal of Medicine</u> , 300:1068-1073 (1979)
CY	AX	Zoll et al., "Generation of cytokine-induced killer cells using exogenous interleukin-2, -7 or -12", <u>Cancer Immunol. Immunother</u> , 47:221-226 (1998)
	AY	
	AZ	
	AAA	
	ABB	
	ACC	
	ADD	
	AEE	
	AFF	
	AGG	
	AHH	
	AII	
	AJJ	
	AKK	
	ALL	

Examiner Signature <i>Chris John H. Van</i>	Date Considered 12-4-02
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	